Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alkaloid AD SkopjeXMAE:ALK -2.35%100 5-Year Yield-on-Cost % is 5.31 as of Jul. 31, 2026, which is 17% above its 10-year median of 4.55. GuruFocus rates XMAE:ALK with a GF Score™ of 100/100 and a GF Value™ of MKD27,499.28 (Modestly Undervalued). Among 512 Drug Manufacturers companies, Alkaloid AD Skopje ranks better than 74.02% on this metric.
Alkaloid AD Skopje's yield on cost for the quarter that ended in Mar. 2026 was 5.31.
The historical rank and industry rank for Alkaloid AD Skopje's 5-Year Yield-on-Cost % or its related term are showing as below:
XMAE:ALK'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3 Med: 4.55 Max: 7.74
Current: 5.31
During the past 13 years, Alkaloid AD Skopje's highest Yield on Cost was 7.74. The lowest was 3.00. And the median was 4.55.
XMAE:ALK's 5-Year Yield-on-Cost % is ranked better than 74.02% of 512
companies
in the Drug Manufacturers industry
Industry Median: 2.32
vs XMAE:ALK: 5.31
Alkaloid AD Skopje (XMAE:ALK) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Alkaloid AD Skopje 5-Year Yield-on-Cost % Related Terms
XMAE:ALK vs ZTS, UTHR, VTRS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Alkaloid AD Skopje's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alkaloid AD Skopje 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Alkaloid AD Skopje's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Alkaloid AD Skopje's 5-Year Yield-on-Cost % falls into.
Alkaloid AD Skopje 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Alkaloid AD Skopje (XMAE:ALK) has a 5-Year Yield-on-Cost % of 5.31 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alkaloid AD Skopje and its competitors. This is 17% above median its historical median of 4.55. Over the past decade, Alkaloid AD Skopje's 5-Year Yield-on-Cost % has ranged from 3.00 to 7.74. According to the industry distribution chart, Alkaloid AD Skopje ranks #133 out of 512 companies in the Drug Manufacturers industry, placing it in the top 26%.
Is Alkaloid AD Skopje's 5-Year Yield-on-Cost % too high?
Alkaloid AD Skopje's current 5-Year Yield-on-Cost % of 5.31 is 17% above median its 10-year median of 4.55. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 7.74. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.32. Alkaloid AD Skopje's value of 5.31 is 128.9% above this industry median. Based on the distribution chart, Alkaloid AD Skopje ranks #133 out of 512 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Alkaloid AD Skopje has a GF Score™ of 100/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alkaloid AD Skopje's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Alkaloid AD Skopje ranks #133 out of 512 companies for 5-Year Yield-on-Cost %. This puts Alkaloid AD Skopje in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.32. Alkaloid AD Skopje's value of 5.31 is 128.9% above this benchmark. Historically, Alkaloid AD Skopje's own 5-Year Yield-on-Cost % has ranged from 3.00 to 7.74 over the past decade. While the company's 10-year median is 4.55 vs. the industry median of 2.32, Alkaloid AD Skopje has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.32, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alkaloid AD Skopje's current 5-Year Yield-on-Cost % of 5.31 is 128.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Alkaloid AD Skopje and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alkaloid AD Skopje's current 5-Year Yield-on-Cost % is 5.31, which is 17% above median its own 10-year median of 4.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkaloid AD Skopje stock overvalued right now?
Based on GuruFocus' analysis, Alkaloid AD Skopje (XMAE:ALK) is currently considered Modestly Undervalued. The stock's GF Value™ is MKD27,499.28, compared to a current price of MKD22,850.00 — trading 16.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.31, which is 17% above median its 10-year median of 4.55 and 128.9% above the Drug Manufacturers industry median of 2.32. Alkaloid AD Skopje's overall GF Score™ is 100/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Alkaloid AD Skopje (XMAE:ALK), the current 5-Year Yield-on-Cost % is 5.31 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alkaloid AD Skopje (XMAE:ALK) Overvalued in 2026?
Based on GuruFocus' analysis, Alkaloid AD Skopje stock appears to be undervalued.
The current stock price of MKD22,850.00 is trading 16.9% below its estimated GF Value™ of MKD27,499.28.
GuruFocus considers Alkaloid AD Skopje to be Modestly Undervalued.
Key valuation signals for XMAE:ALK:
5-Year Yield-on-Cost %: 5.31 (17% above median its 10-year median of 4.55)
GF Value™: MKD27,499.28 vs. price of MKD22,850.00 (16.9% below fair value)
Industry Position: 128.9% above the Drug Manufacturers median (#133 of 512)
No single metric tells the full story. See the XMAE:ALK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals. It derives maximum revenue from Pharmaceuticals products segment.
100GF Score
Get the complete analysis for XMAE:ALK
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAE:ALK has been successfully added to your 
